ROCKVILLE, MD , Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data from TZIELD®

ROCKVILLE, MD , July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC) Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nine months Conference call

ROCKVILLE, MD , May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results

ROCKVILLE, MD , April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

ROCKVILLE, MD , March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S.

Cash runway extended through 2025 with $ 250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readout Encouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy clinical data presented at ASCO-GU

ROCKVILLE, MD , March 08, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sell

ROCKVILLE, MD , March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, MD , March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90) Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partial

ROCKVILLE, MD , Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

ROCKVILLE, MD , Jan. 04, 2023 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41 st Annual J.P.

ROCKVILLE, MD , Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A.

ROCKVILLE, MD , Nov. 17, 2022 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S.

Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end Anticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy clinical data in first

ROCKVILLE, MD , Nov. 02, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

ROCKVILLE, MD , Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

– Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART ® Molecule with Potential to Treat Various Hematologic Malignancies – –   Potential for Companies to Collaborate on Two Additional Future Research Programs – FOSTER CITY, Calif. & ROCKVILLE, Md. --(BUSINESS WIRE)--Oct.

ROCKVILLE, MD , Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2/3 study in prostate cancer by year-end Initiates cost-saving measures through corporate restructuring with focus on key clinical programs, extending cash runway into 2024 with

ROCKVILLE, MD , July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, MD , July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of July 7, 2022 , the Company closed the

ROCKVILLE, MD , June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the